Energy 1 Corp. is a shell purchased by Shanghai Yicheng Culture Communication, a subsidiary of Pango Group of China. On the below Pangbo website you will find many references to EGOC. It is anticipated that Pango Group will reverse merge into EGOC.
https://www.otcmarkets.com/stock/EGOC/disclosure
https://www.otcmarkets.com/stock/EGOC/security
http://www.zgpangbo.com/index.html
Pangbo Group was established in 2016 with its headquarters in Hainan. In 2017, branches were set up in Beijing, Hainan, Shanghai, Guangzhou and Shandong respectively. The company is committed to building a domestic innovative high-end health technology platform, with industrialization as the core, developing innovative medical treatment, ecological construction, health management, film and television media, integrated national health industry chain. In 2019, at the invitation of Heze Municipal Government, Pangbo Group joined hands and officially settled in Heze, and signed a long-term strategic cooperation agreement (joint research and development) with Heze Zhushi Pharmaceutical in the same year. Pangbo Group is committed to building a big health industry chain. Since its establishment, it has always adhered to the principle of people-oriented and honest management. It has gathered industry elites, combined advanced foreign information technology, management methods and corporate experience with the specific reality of domestic enterprises. Provide a full range of solutions to help enterprises improve management level and production capacity, so that enterprises can always maintain competitiveness in the fierce market competition, and achieve rapid and stable development of enterprises. The group company has more than 500 employees across the country, and has more than 100 personnel with various professional and economic and technical titles, including 60 personnel with intermediate and senior professional titles, 150 graduates from double-first-class universities, and 1 senior executive of a Fortune 500 company. Served as executives of 8 large domestic listed companies. More than 200 large-scale medical devices have been developed. In 2019, it was rated as "2019 New Entrepreneurial Enterprise" by Shenzhen Cultural Investment Office.